TSLP-Binding Antibody Fragments for Asthma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for TSLP-related inflammatory conditions, such as asthma, lack effective molecules that specifically bind to thymic stromal lymphopoietin (TSLP), leading to inadequate control of allergic inflammation and airway hyperreactivity.
Innovation Solution
Development of monoclonal antibodies or antibody fragments, including Fab, Fab′, F(ab′)2, scFv, minibody, or diabody, that specifically bind to human TSLP with high affinity, comprising specific heavy and light chain complementarity determining regions (CDRs), formulated into pharmaceutical compositions for inhalation to target TSLP in the lungs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for TSLP-related inflammatory conditions, then treatment options are available, but effective control of allergic inflammation and airway hyperreactivity is inadequate
Solution Approach 1:
The patent introduces TSLP-binding molecules (monoclonal antibodies or antibody fragments) as intermediary substances that specifically bind to TSLP cytokine, blocking its interaction with receptors and thereby mediating the therapeutic effect. This intermediary approach provides both specificity to the TSLP target and reliable therapeutic control of allergic inflammation.
Solution Approach 2:
The patent employs parameter changes by developing molecules with optimized binding affinity parameters (KD values) to TSLP. By adjusting the molecular parameters of the antibody fragments and their CDR regions, the treatment achieves both high specificity for TSLP and reliable therapeutic effectiveness in controlling inflammatory conditions.
2Reliability
If TSLP-binding molecules are developed with high affinity, then neutralization of TSLP is effective, but manufacturing complexity increases
Solution Approach 1:
The patent segments the antibody molecule into smaller functional units, specifically using antibody fragments (Fab, Fab', F(ab')2, scFv, minibody, diabody) rather than complete IgG molecules. This segmentation maintains the essential TSLP-binding function through preserved CDR regions while simplifying the overall molecular structure and potentially easing manufacturing complexity.
Solution Approach 2:
The patent extracts and utilizes only the essential antigen-binding portions (CDR regions of heavy and light chains) required for high-affinity TSLP binding, removing unnecessary portions of the antibody molecule. This extraction approach achieves high binding affinity with simplified molecular structures that are easier to manufacture.
3Ease of operation
If monoclonal antibodies are formulated for inhalation, then direct delivery to lungs is achieved, but formulation complexity increases
Solution Approach 1:
The patent employs inhalation formulation that leverages the patient's own respiratory system to deliver the medication directly to the lungs. The inhaled formulation utilizes natural breathing mechanics to achieve site-specific delivery, reducing the need for complex delivery devices while maintaining ease of operation through patient self-administration.
Data Source
AI summary
The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.